PT-141 (Bremelanotide)
A melanocortin receptor agonist that directly activates the CNS to increase sexual desire and function.
⚠ Research & Educational Use Only. PT-141 (Bremelanotide) is a research chemical documented here for scientific education. All information references peer-reviewed literature and preclinical/clinical study data. Not for human consumption. Not medical advice. Consult a licensed researcher or healthcare professional before any laboratory use.
- Increases sexual desire and libido in men and women
- Effective for erectile dysfunction even when PDE5 inhibitors fail
- Works via CNS activation — addresses psychological component of sexual dysfunction
- PT-141 (Bremelanotide) is not FDA-approved for human use. It is a research chemical for scientific study only.
Research At a Glance
- Increases sexual desire and libido in men and women
- Effective for erectile dysfunction even when PDE5 inhibitors fail
- Works via CNS activation — addresses psychological component of sexual dysfunction
- FDA-approved (Vyleesi) for HSDD in premenopausal women
What is PT-141 (Bremelanotide)?
PT-141 (Bremelanotide) is a synthetic cyclic heptapeptide derived from Melanotan II, developed by Palatin Technologies. Unlike traditional erectile dysfunction drugs that work by increasing blood flow to the genitals, PT-141 works by directly activating melanocortin receptors (MC3R and MC4R) in the central nervous system, specifically in the hypothalamus, to increase sexual motivation and desire. This central mechanism of action makes it effective for both men and women. It received FDA approval in 2019 as Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women — the first non-hormonal treatment for female sexual dysfunction.
Key Research Benefits
Documented effects observed in preclinical and clinical studies on PT-141 (Bremelanotide). See all Sexual Health peptides for comparison.
Common Stacks
PT-141 (Bremelanotide) is frequently combined with the following peptides for synergistic effects. Click any peptide to compare profiles before deciding.
Both are melanocortin-based sexual function compounds - PT-141 is the selective successor to Melanotan II for sexual arousal without tanning.
Oxytocin's pro-bonding and anxiety-reducing effects complement PT-141's physical arousal mechanism for a comprehensive intimacy protocol.
Side Effects & Risks
Adverse effects reported in the research literature. All data sourced from preclinical and clinical study reports.
Dosing Data from the Literature
Doses referenced below are sourced from published preclinical and clinical studies. Use the peptide dose calculator to convert these values to injection volume.
Typical research dosing: 0.5–2 mg subcutaneously, 1–2 hours before sexual activity. Start with 0.5 mg to assess tolerance. Maximum recommended dose is 2 mg. Do not use more than once per 72 hours due to prolonged action.
Administration in Research Settings
Standard reconstitution and administration methodology for laboratory research use.
Reconstitute with bacteriostatic water, administer subcutaneously (abdomen or thigh). Administer 1–2 hours before desired effect. Pre-medicate with an antiemetic (e.g., ondansetron) if nausea is a concern. Lying down after injection can reduce nausea. Avoid high-fat meals before use.
Research Video
Explore Further
Quick Reference
Research Articles
View all research articlesResearch Use Only
This information is for educational research purposes only. This is not medical advice. Consult a qualified healthcare professional.